LEADER 03359nam 2200625Ia 450 001 9910140832103321 005 20200520144314.0 010 $a1-118-04358-8 010 $a1-282-70798-1 010 $a9786612707988 010 $a0-470-76982-3 010 $a0-470-76981-5 035 $a(CKB)2670000000035575 035 $a(EBL)564964 035 $a(OCoLC)662453076 035 $a(SSID)ssj0000411457 035 $a(PQKBManifestationID)11271677 035 $a(PQKBTitleCode)TC0000411457 035 $a(PQKBWorkID)10357017 035 $a(PQKB)10892099 035 $a(MiAaPQ)EBC564964 035 $a(Au-PeEL)EBL564964 035 $a(CaPaEBR)ebr10411511 035 $a(CaONFJC)MIL270798 035 $a(PPN)240450396 035 $a(EXLCZ)992670000000035575 100 $a20100302d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAggregation of therapeutic proteins$b[electronic resource] /$fedited by Wei Wang, Christopher J. Roberts 210 $aHoboken, NJ $cWiley$dc2010 215 $a1 online resource (514 p.) 300 $aDescription based upon print version of record. 311 $a0-470-41196-1 320 $aIncludes bibliographical references and index. 327 $aAGGREGATION OF THERAPEUTIC PROTEINS; CONTENTS; PREFACE; CONTRIBUTORS; CHAPTER 1: Fundamental Structures and Behaviors of Proteins; CHAPTER 2: Protein Aggregation Pathways, Kinetics, and Thermodynamics; CHAPTER 3: Identification and Impact of Aggregation-Prone Regions in Proteins and Therapeutic Monoclonal Antibodies; CHAPTER 4: External Factors Affecting Protein Aggregation; CHAPTER 5: Experimental Detection and Characterization of Protein Aggregates; CHAPTER 6: Approaches to Control Protein Aggregation during Bulk Production 327 $aCHAPTER 7: Protein Aggregation and Particle Formation: Effects of Formulation, Interfaces, and Drug Product Manufacturing OperationsCHAPTER 8: Approaches to Managing Protein Aggregation in Product Development; CHAPTER 9: Case Studies Involving Protein Aggregation; CHAPTER 10: Aggregation and Immunogenicity of Therapeutic Proteins; CHAPTER 11: Regulatory Perspective on Aggregates as a Product Quality Attribute; INDEX; color plate 330 $aThis book gives pharmaceutical scientists an up-to-date resource on protein aggregation and its consequences, and available methods to control or slow down the aggregation process. While significant progress has been made in the past decade, the current understanding of protein aggregation and its consequences is still immature. Prevention or even moderate inhibition of protein aggregation has been mostly experimental. The knowledge in this book can greatly help pharmaceutical scientists in the development of therapeutic proteins, and also instigate further scientific investigations in this ar 606 $aProtein drugs 606 $aAggregation (Chemistry) 615 0$aProtein drugs. 615 0$aAggregation (Chemistry) 676 $a615.5/8 701 $aWang$b Wei$f1957 Mar. 10-$0914317 701 $aRoberts$b Christopher John$f1972-$0914318 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910140832103321 996 $aAggregation of therapeutic proteins$92048463 997 $aUNINA